Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension

INCLUSION: * Self-reported/self-identified as Black or African American * Resting systolic blood pressure of 120 to \<150 mm Hg and diastolic blood pressure \<100 mm Hg * Residence in communities identified as Boston area food deserts: Brighton, Chelsea, Dorchester, East Boston, Everett, Hyde Park, Jamaica Plain, Malden, Mattapan, Revere, Roslindale, Roxbury, or Winthrop * Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 12-week period * Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service * Have access to mobile device or computer to be able to conduct grocery orders via video conference or by phone * Willing and able to complete required measurement procedures EXCLUSION: Laboratory Exclusions: * Serum potassium ≥5.0 mmol/L or \<3.5 mmol/L * Estimated glomerular filtration rate (eGFR) \<30 mL/min per 1.73 m\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation * Hemoglobin A1c ≥6.5% Medication Exclusions: * Any use of medications that lower blood pressure or medications intended for hypertension treatment (including antihypertensives taken for non-hypertension purposes) within the last 6 months * Unstable doses (i.e. a change in the 2 months prior to screening or randomization) of the following: * Sodium-glucose co-transporter 2 (SGLT2) inhibitors * Stimulants * Inhaled or oral medications for asthma or chronic obstructive pulmonary disease (COPD) * Hormone replacement therapy or thyroid hormone * Weight-increasing psychotropic agents, including antipsychotic agents, lithium, and mirtazapine * Use of any of the following medications: * Potassium supplement, except if part of a multivitamin * Warfarin (Coumadin) * Chronic oral corticosteroid (intermittent use is okay) * Weight loss medications (including GLP-1 receptor agonists) * Unwillingness to keep same dose of vitamin, mineral, and botanical supplements * Any medication not compatible with participation as determined by the investigators Physical Exclusions: * Systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg * Body weight \>420 pounds * Arm circumference \>50cm * Weight loss or gain of \>5.0% of body weight during prior 2 months Medical History Exclusions: * Type 1 or Type 2 Diabetes defined as a hemoglobin A1c ≥6.5% or diabetes treatment * Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission * Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable) * Active inflammatory bowel disease, bowel resection, malabsorptive syndrome, pancreatitis (episode within past year), or history of bariatric surgery * Pregnancy or lactation or planned pregnancy * Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months * Any other serious illness or condition not compatible with participation as determined by the investigators Lifestyle and Other Exclusions: * Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence * Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week * Active substance use disorder that would interfere with participation * Extreme food insecurity * Participation in or planning to start weight loss program * Current participation in another clinical trial that could interfere with the study protocol * Anticipated change in residence prior to the end of the study * Families with more than 6 adults at dinner time (children are considered to be half an adult) * Investigator discretion